Fri, Aug 1, 2014, 4:54 AM EDT - U.S. Markets open in 4 hrs 36 mins

Recent

% | $
Click the to save as a favorite.

ImmunoCellular Therapeutics, Ltd. Message Board

fkofranklin1 3 posts  |  Last Activity: Jun 18, 2014 4:42 PM Member since: Oct 27, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • fkofranklin1 fkofranklin1 Jun 18, 2014 4:42 PM Flag

    Nice explanation except for the fact that management does know the enrollment numbers but don't plan on sharing the info. How else can they estimate enrollment completion and make revisions to that date. One positive is that the clinical sites is up to 66 from 51 so hopefully enrollment will be finished by year end but we will see.

  • Reply to

    CUT THE IRRATIONAL COMMENTS

    by wm.craigbarnard Jun 15, 2014 3:51 PM
    fkofranklin1 fkofranklin1 Jun 16, 2014 10:07 AM Flag

    what's your opinion about the impact of cbst's drug approval that's coming up on DRTX's sp?

  • Reply to

    How does this data compare to

    by zoomlik May 5, 2014 9:06 AM
    fkofranklin1 fkofranklin1 May 5, 2014 9:51 AM Flag

    Should first-line treatment for advanced or metastatic soft tissue sarcoma be doxorubicin alone or with ifosfamide? Between April 2003 and May 2010, EORTC trial 62012 randomized 455 patients aged 18 to 60 years with unresectable locally advanced or metastatic high-grade soft-tissue sarcoma to receive either doxorubicin alone (228 patients) or intensified doxorubicin plus ifosfamide (227 patients, combination group) as first-line treatment. At a median follow-up of 56 months in the doxorubicin alone group and 59 months in the combination group, no significant difference was observed in median overall survival (12.8 months [95·5% CI 10·5 - 14·3] in the doxorubicin alone group and 14.3 months [12.5 – 16.5] in the combination group; hazard ratio [HR] 0.83 [95.5% CI 0.67 - 1.03]; stratified logrank test p = 0.076). Median progression-free survival was significantly higher in the combination group (7.4 months [95% CI 6.6 – 8.3]) than for the doxorubicin alone group (4.6 months [2.9 - 5·6]; HR 0.74 [95% CI 0.60 – 0.90], stratified log-rank test p = 0.003). More patients in the doxorubicin and ifosfamide group than in the doxorubicin alone group had an overall response (26% versus 14%; p

IMUC
0.98-0.02(-1.99%)Jul 31 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Tesla Motors, Inc.
NasdaqGSThu, Jul 31, 2014 4:00 PM EDT
eHealth, Inc.
NasdaqGSThu, Jul 31, 2014 3:59 PM EDT